5 O
WARNINGS O
AND O
PRECAUTIONS O
EXCERPT O
: O
* O
Cerebrovascular O
Adverse O
Reactions O
in O
Elderly O
Patients O
with O
Dementia-Related O
Psychosis O
: O
Increased O
incidence O
of O
cerebrovascular O
adverse O
events O
( O
e.g. O
, O
stroke O
, O
transient O
ischemic O
attack O
) O
( O
5.2 O
) O
. O

* O
Neuroleptic O
Malignant O
Syndrome O
: O
Manage O
with O
immediate O
discontinuation O
and O
close O
monitoring O
( O
5.4 O
) O
. O

* O
Tardive O
Dyskinesia O
: O
Discontinue O
if O
clinically O
appropriate O
( O
5.5 O
) O
. O

* O
* O
- O
Hyperglycemia O
and O
Diabetes O
Mellitus O
: O
Monitor O
patients O
for O
symptoms O
of O
hyperglycemia O
including O
polydipsia O
, O
polyuria O
, O
polyphagia O
, O
and O
weakness O
. O

Monitor O
glucose O
regularly O
in O
patients O
with O
diabetes O
or O
at O
risk O
for O
diabetes O
. O

* O
- O
Dyslipidemia O
: O
Undesirable O
alterations O
have O
been O
observed O
in O
patients O
treated O
with O
atypical O
antipsychotics O
. O

* O
- O
Weight O
Gain O
: O
Gain O
in O
body O
weight O
has O
been O
observed O
. O

Monitor O
weight O
. O

Metabolic O
Changes O
: O
Atypical O
antipsychotic O
drugs O
have O
been O
associated O
with O
metabolic O
changes O
that O
may O
increase O
cardiovascular/cerebrovascular O
risk O
. O

These O
metabolic O
changes O
include O
hyperglycemia O
, O
dyslipidemia O
, O
and O
weight O
gain O
( O
5.6 O
) O
. O

* O
Hyperprolactinemia O
: O
Prolactin O
elevations O
may O
occur O
( O
5.7 O
) O
. O

* O
Leukopenia O
, O
Neutropenia O
, O
and O
Agranulocytosis O
: O
Perform O
complete O
blood O
counts O
( O
CBC O
) O
in O
patients O
with O
a O
pre-existing O
low O
white O
blood O
cell O
count O
( O
WBC O
) O
or O
a O
history O
of O
leukopenia O
or O
neutropenia O
. O

Consider O
discontinuing O
LATUDA O
if O
a O
clinically O
significant O
decline O
in O
WBC O
occurs O
in O
the O
absence O
of O
other O
causative O
factors O
( O
5.8 O
) O
. O

* O
Orthostatic O
Hypotension O
and O
Syncope O
: O
Dizziness O
, O
tachycardia O
or O
bradycardia O
, O
and O
syncope O
may O
occur O
, O
especially O
early O
in O
treatment O
. O

In O
patients O
with O
known O
cardiovascular O
or O
cerebrovascular O
disease O
, O
and O
in O
antipsychotic-naive O
patients O
, O
consider O
a O
lower O
starting O
dose O
and O
slower O
titration O
( O
5.9 O
) O
. O

5.1 O
Increased O
Mortality O
in O
Elderly O
Patients O
with O
Dementia-Related O
Psychosis O
Elderly O
patients O
with O
dementia B-Not_AE_Candidate
- I-Not_AE_Candidate
related I-Not_AE_Candidate
psychosis I-Not_AE_Candidate
treated O
with O
antipsychotic O
drugs O
are O
at O
an O
increased O
risk O
of O
death B-NonOSE_AE
. O

Analyses O
of O
17 O
placebo-controlled O
trials O
( O
modal O
duration O
of O
10 O
weeks O
) O
, O
largely O
in O
patients O
taking O
atypical O
antipsychotic O
drugs O
, O
revealed O
a O
risk O
of O
death B-NonOSE_AE
in O
drug-treated O
patients O
of O
between O
1.6- O
to O
1.7-times O
the O
risk O
of O
death B-NonOSE_AE
in O
placebo-treated O
patients O
. O

Over O
the O
course O
of O
a O
typical O
10-week O
controlled O
trial O
, O
the O
rate O
of O
death B-NonOSE_AE
in O
drug-treated O
patients O
was O
about O
4.5 O
% O
, O
compared O
to O
a O
rate O
of O
about O
2.6 O
% O
in O
the O
placebo O
group O
. O

Although O
the O
causes O
of O
death B-NonOSE_AE
were O
varied O
, O
most O
of O
the O
deaths B-NonOSE_AE
appeared O
to O
be O
either O
cardiovascular O
( O
e.g. O
, O
heart B-NonOSE_AE
failure I-NonOSE_AE
, O
sudden B-NonOSE_AE
death I-NonOSE_AE
) O
or O
infectious B-NonOSE_AE
( O
e.g. O
, O
pneumonia B-NonOSE_AE
) O
in O
nature O
. O

Observational O
studies O
suggest O
that O
, O
similar O
to O
atypical O
antipsychotic O
drugs O
, O
treatment O
with O
conventional O
antipsychotic O
drugs O
may O
increase B-NonOSE_AE
mortality I-NonOSE_AE
. O

The O
extent O
to O
which O
the O
findings O
of O
increased B-NonOSE_AE
mortality I-NonOSE_AE
in O
observational O
studies O
may O
be O
attributed O
to O
the O
antipsychotic O
drug O
as O
opposed O
to O
some O
characteristic O
( O
s O
) O
of O
the O
patients O
is O
not O
clear O
. O

LATUDA O
is O
not O
approved O
for O
the O
treatment O
of O
patients O
with O
dementia B-Not_AE_Candidate
- I-Not_AE_Candidate
related I-Not_AE_Candidate
psychosis I-Not_AE_Candidate
[ O
see O
Boxed O
Warning O
] O
. O

5.2 O
Suicidal O
Thoughts O
and O
Behaviors O
in O
Adolescents O
and O
Young O
Adults O
Patients O
with O
major B-Not_AE_Candidate
depressive I-Not_AE_Candidate
disorder I-Not_AE_Candidate
( I-Not_AE_Candidate
MDD I-Not_AE_Candidate
) O
, O
both O
adult O
and O
pediatric O
, O
may O
experience O
worsening B-NonOSE_AE
of I-NonOSE_AE
their I-NonOSE_AE
depression I-NonOSE_AE
and/or O
the O
emergence O
of O
suicidal B-NonOSE_AE
ideation I-NonOSE_AE
and O
behavior O
( O
suicidality O
) O
or O
unusual B-NonOSE_AE
changes I-NonOSE_AE
in I-NonOSE_AE
behavior I-NonOSE_AE
, O
whether O
or O
not O
they O
are O
taking O
antidepressant O
medications O
, O
and O
this O
risk O
may O
persist O
until O
significant O
remission O
occurs O
. O

Suicide B-NonOSE_AE
is O
a O
known O
risk O
of O
depression B-NonOSE_AE
and O
certain O
other O
psychiatric B-NonOSE_AE
disorders I-NonOSE_AE
, O
and O
these O
disorders O
themselves O
are O
the O
strongest O
predictors O
of O
suicide B-NonOSE_AE
. O

There O
has O
been O
a O
long-standing O
concern O
, O
however O
, O
that O
antidepressants O
may O
have O
a O
role O
in O
inducing O
worsening B-OSE_Labeled_AE
of I-OSE_Labeled_AE
depression I-OSE_Labeled_AE
and O
the O
emergence B-OSE_Labeled_AE
of I-OSE_Labeled_AE
suicidality I-OSE_Labeled_AE
in O
certain O
patients O
during O
the O
early O
phases O
of O
treatment O
. O

Pooled O
analyses O
of O
short-term O
placebo-controlled O
trials O
of O
antidepressant O
drugs O
( O
SSRIs O
and O
others O
) O
showed O
that O
these O
drugs O
increase O
the O
risk O
of O
suicidal B-OSE_Labeled_AE
thinking I-OSE_Labeled_AE
and O
behavior O
( O
suicidality O
) O
in O
children O
, O
adolescents O
, O
and O
young O
adults O
( O
ages O
18-24 O
) O
with O
major B-Not_AE_Candidate
depressive I-Not_AE_Candidate
disorder I-Not_AE_Candidate
( I-Not_AE_Candidate
MDD I-Not_AE_Candidate
) O
and O
other O
psychiatric B-Not_AE_Candidate
disorders I-Not_AE_Candidate
. O

Short-term O
studies O
did O
not O
show O
an O
increase B-NonOSE_AE
in I-NonOSE_AE
the I-NonOSE_AE
risk I-NonOSE_AE
of I-NonOSE_AE
suicidality I-NonOSE_AE
with O
antidepressants O
compared O
to O
placebo O
in O
adults O
beyond O
age O
24 O
; O
there O
was O
a O
reduction O
with O
antidepressants O
compared O
to O
placebo O
in O
adults O
aged O
65 O
and O
older O
. O

The O
pooled O
analyses O
of O
placebo-controlled O
trials O
in O
children O
and O
adolescents O
with O
MDD B-Not_AE_Candidate
, O
obsessive B-Not_AE_Candidate
compulsive I-Not_AE_Candidate
disorder I-Not_AE_Candidate
( I-Not_AE_Candidate
OCD I-Not_AE_Candidate
) O
, O
or O
other O
psychiatric B-Not_AE_Candidate
disorders I-Not_AE_Candidate
included O
a O
total O
of O
24 O
short-term O
trials O
of O
9 O
antidepressant O
drugs O
in O
over O
4400 O
patients O
. O

The O
pooled O
analyses O
of O
placebo-controlled O
trials O
in O
adults O
with O
MDD B-Not_AE_Candidate
or O
other O
psychiatric B-Not_AE_Candidate
disorders I-Not_AE_Candidate
included O
a O
total O
of O
295 O
short-term O
trials O
( O
median O
duration O
of O
2 O
months O
) O
of O
11 O
antidepressant O
drugs O
in O
over O
77,000 O
patients O
. O

There O
was O
considerable O
variation O
in O
risk O
of O
suicidality B-NonOSE_AE
among O
drugs O
, O
but O
a O
tendency O
toward O
an O
increase O
in O
the O
younger O
patients O
for O
almost O
all O
drugs O
studied O
. O

There O
were O
differences O
in O
absolute O
risk O
of O
suicidality B-NonOSE_AE
across O
the O
different O
indications O
, O
with O
the O
highest O
incidence O
in O
MDD B-Not_AE_Candidate
. O

The O
risk O
of O
differences O
( O
drug O
vs O
. O
placebo O
) O
, O
however O
, O
were O
relatively O
stable O
within O
age O
strata O
and O
across O
indications O
. O

These O
risk O
differences O
( O
drug-placebo O
difference O
in O
the O
number O
of O
cases O
of O
suicidality O
per O
1000 O
patients O
treated O
) O
are O
provided O
in O
Table O
2 O
. O

Table O
2 O
Age O
Range O
Drug-Placebo O
Difference O
in O
Number O
of O
Cases O
of O
Suicidality B-OSE_Labeled_AE
per O
1000 O
Patients O
Treated O
Increases I-OSE_Labeled_AE
Compared O
to O
Placebo O
< O
18 O
14 O
additional O
cases O
18-24 O
5 O
additional O
cases O
Decreases O
Compared O
to O
Placebo O
25-64 O
1 O
fewer O
case O
> O
=65 O
6 O
fewer O
cases O
No O
suicides B-NonOSE_AE
occurred O
in O
any O
of O
the O
pediatric O
trials O
. O

There O
were O
suicides B-NonOSE_AE
in O
the O
adult O
trials O
, O
but O
the O
number O
was O
not O
sufficient O
to O
reach O
any O
conclusion O
about O
drug O
effect O
on O
suicide B-NonOSE_AE
. O

It O
is O
unknown O
whether O
the O
suicidality B-NonOSE_AE
risk I-NonOSE_AE
extends O
to O
longer-term O
use O
, O
i.e. O
, O
beyond O
several O
months O
. O

However O
, O
there O
is O
substantial O
evidence O
from O
placebo-controlled O
maintenance O
trials O
in O
adults O
with O
depression B-Not_AE_Candidate
that O
the O
use O
of O
antidepressants O
can O
delay O
the O
recurrence O
of O
depression B-Not_AE_Candidate
. O

All O
patients O
being O
treated O
with O
antidepressants O
for O
any O
indication O
should O
be O
monitored O
appropriately O
and O
observed O
closely O
for O
clinical O
worsening O
, O
suicidality B-NonOSE_AE
, O
and O
unusual B-NonOSE_AE
changes I-NonOSE_AE
in I-NonOSE_AE
behavior I-NonOSE_AE
, O
especially O
during O
the O
initial O
few O
months O
of O
a O
course O
of O
drug O
therapy O
, O
or O
at O
times O
of O
dose O
changes O
, O
either O
increases O
or O
decreases O
. O

The O
following O
symptoms O
, O
anxiety B-OSE_Labeled_AE
, O
agitation B-OSE_Labeled_AE
, O
panic B-OSE_Labeled_AE
attacks I-OSE_Labeled_AE
, O
insomnia B-OSE_Labeled_AE
, O
irritability B-OSE_Labeled_AE
, O
hostility B-OSE_Labeled_AE
, O
aggressiveness B-OSE_Labeled_AE
, O
impulsivity B-OSE_Labeled_AE
, O
akathisia B-OSE_Labeled_AE
( O
psychomotor B-OSE_Labeled_AE
restlessness I-OSE_Labeled_AE
) O
, O
hypomania B-OSE_Labeled_AE
, O
and O
mania B-OSE_Labeled_AE
, O
have O
been O
reported O
in O
adult O
and O
pediatric O
patients O
being O
treated O
with O
antidepressants O
for O
major B-Not_AE_Candidate
depressive I-Not_AE_Candidate
disorder I-Not_AE_Candidate
as O
well O
as O
for O
other O
indications O
, O
both O
psychiatric B-Not_AE_Candidate
and O
nonpsychiatric O
. O

Although O
a O
causal O
link O
between O
the O
emergence O
of O
such O
symptoms O
and O
either O
the O
worsening B-NonOSE_AE
of I-NonOSE_AE
depression I-NonOSE_AE
and/or O
the O
emergence O
of O
suicidal B-NonOSE_AE
impulses I-NonOSE_AE
has O
not O
been O
established O
, O
there O
is O
concern O
that O
such O
symptoms O
may O
represent O
precursors O
to O
emerging O
suicidality B-NonOSE_AE
. O

Consideration O
should O
be O
given O
to O
changing O
the O
therapeutic O
regimen O
, O
including O
possibly O
discontinuing O
the O
medication O
, O
in O
patients O
whose O
depression B-Not_AE_Candidate
is O
persistently O
worse O
, O
or O
who O
are O
experiencing O
emergent B-NonOSE_AE
suicidality I-NonOSE_AE
or O
symptoms O
that O
might O
be O
precursors O
to O
worsening O
depression B-NonOSE_AE
or O
suicidality B-NonOSE_AE
, O
especially O
if O
these O
symptoms O
are O
severe O
, O
abrupt O
in O
onset O
, O
or O
were O
not O
part O
of O
the O
patient O
's O
presenting O
symptoms O
. O

Families O
and O
caregivers O
of O
patients O
being O
treated O
with O
antidepressants O
for O
major B-Not_AE_Candidate
depressive I-Not_AE_Candidate
disorder I-Not_AE_Candidate
or O
other O
indications O
, O
both O
psychiatric B-Not_AE_Candidate
and O
nonpsychiatric O
, O
should O
be O
alerted O
about O
the O
need O
to O
monitor O
patients O
for O
the O
emergence O
of O
agitation B-NonOSE_AE
, O
irritability B-NonOSE_AE
, O
unusual B-NonOSE_AE
changes I-NonOSE_AE
in I-NonOSE_AE
behavior I-NonOSE_AE
, O
and O
the O
other O
symptoms O
described O
above O
, O
as O
well O
as O
the O
emergence O
of O
suicidal B-NonOSE_AE
thoughts I-NonOSE_AE
and O
behaviors O
, O
and O
to O
report O
such O
symptoms O
immediately O
to O
health O
care O
providers O
. O

Such O
monitoring O
should O
include O
daily O
observation O
by O
families O
and O
caregivers O
. O

Prescriptions O
for O
LATUDA O
should O
be O
written O
for O
the O
smallest O
quantity O
of O
capsules O
consistent O
with O
good O
patient O
management O
, O
in O
order O
to O
reduce O
the O
risk O
of O
overdose O
. O

5.3 O
Cerebrovascular O
Adverse O
Reactions O
, O
Including O
Stroke O
in O
Elderly O
Patients O
with O
Dementia-Related O
Psychosis O
In O
placebo-controlled O
trials O
with O
risperidone O
, O
aripiprazole O
, O
and O
olanzapine O
in O
elderly O
subjects O
with O
dementia B-Not_AE_Candidate
, O
there O
was O
a O
higher O
incidence O
of O
cerebrovascular B-OSE_Labeled_AE
adverse I-OSE_Labeled_AE
reactions I-OSE_Labeled_AE
( O
cerebrovascular B-OSE_Labeled_AE
accidents I-OSE_Labeled_AE
and O
transient B-OSE_Labeled_AE
ischemic I-OSE_Labeled_AE
attacks I-OSE_Labeled_AE
) O
, O
including O
fatalities B-NonOSE_AE
, O
compared O
to O
placebo-treated O
subjects O
. O

LATUDA O
is O
not O
approved O
for O
the O
treatment O
of O
patients O
with O
dementia B-Not_AE_Candidate
- I-Not_AE_Candidate
related I-Not_AE_Candidate
psychosis I-Not_AE_Candidate
[ O
see O
also O
Boxed O
Warning O
and O
Warnings O
and O
Precautions O
( O
5.1 O
) O
] O
. O

5.4 O
Neuroleptic O
Malignant O
Syndrome O
A O
potentially O
fatal B-NonOSE_AE
symptom O
complex O
sometimes O
referred O
to O
as O
Neuroleptic B-OSE_Labeled_AE
Malignant I-OSE_Labeled_AE
Syndrome I-OSE_Labeled_AE
( I-OSE_Labeled_AE
NMS I-OSE_Labeled_AE
) O
has O
been O
reported O
in O
association O
with O
administration O
of O
antipsychotic O
drugs O
, O
including O
LATUDA O
. O

Clinical O
manifestations O
of O
NMS B-NonOSE_AE
are O
hyperpyrexia B-NonOSE_AE
, O
muscle B-NonOSE_AE
rigidity I-NonOSE_AE
, O
altered B-NonOSE_AE
mental I-NonOSE_AE
status I-NonOSE_AE
, O
and O
evidence O
of O
autonomic B-NonOSE_AE
instability I-NonOSE_AE
( O
irregular B-NonOSE_AE
pulse I-NonOSE_AE
or O
blood O
pressure O
, O
tachycardia B-NonOSE_AE
, O
diaphoresis B-NonOSE_AE
, O
and O
cardiac B-NonOSE_AE
dysrhythmia I-NonOSE_AE
) O
. O

Additional O
signs O
may O
include O
elevated B-NonOSE_AE
creatine I-NonOSE_AE
phosphokinase I-NonOSE_AE
, O
myoglobinuria B-NonOSE_AE
( O
rhabdomyolysis B-NonOSE_AE
) O
, O
and O
acute B-NonOSE_AE
renal I-NonOSE_AE
failure I-NonOSE_AE
. O

The O
diagnostic O
evaluation O
of O
patients O
with O
this O
syndrome O
is O
complicated O
. O

It O
is O
important O
to O
exclude O
cases O
where O
the O
clinical O
presentation O
includes O
both O
serious O
medical O
illness O
( O
e.g. O
, O
pneumonia B-NonOSE_AE
, O
systemic B-NonOSE_AE
infection I-NonOSE_AE
) O
and O
untreated O
or O
inadequately O
treated O
extrapyramidal B-NonOSE_AE
signs I-NonOSE_AE
and I-NonOSE_AE
symptoms I-NonOSE_AE
( I-NonOSE_AE
EPS I-NonOSE_AE
) O
. O

Other O
important O
considerations O
in O
the O
differential O
diagnosis O
include O
central B-NonOSE_AE
anticholinergic I-NonOSE_AE
toxicity I-NonOSE_AE
, O
heat B-NonOSE_AE
stroke I-NonOSE_AE
, O
drug B-NonOSE_AE
fever I-NonOSE_AE
, O
and O
primary O
central O
nervous O
system O
pathology O
. O

The O
management O
of O
NMS B-NonOSE_AE
should O
include O
: O
1 O
) O
immediate O
discontinuation O
of O
antipsychotic O
drugs O
and O
other O
drugs O
not O
essential O
to O
concurrent O
therapy O
; O
2 O
) O
intensive O
symptomatic O
treatment O
and O
medical O
monitoring O
; O
and O
3 O
) O
treatment O
of O
any O
concomitant O
serious O
medical O
problems O
for O
which O
specific O
treatments O
are O
available O
. O

There O
is O
no O
general O
agreement O
about O
specific O
pharmacological O
treatment O
regimens O
for O
NMS B-NonOSE_AE
. O

If O
a O
patient O
requires O
antipsychotic O
drug O
treatment O
after O
recovery O
from O
NMS B-NonOSE_AE
, O
the O
potential O
reintroduction O
of O
drug O
therapy O
should O
be O
carefully O
considered O
. O

If O
reintroduced O
, O
the O
patient O
should O
be O
carefully O
monitored O
, O
since O
recurrences O
of O
NMS B-NonOSE_AE
have O
been O
reported O
. O

5.5 O
Tardive O
Dyskinesia O
Tardive B-OSE_Labeled_AE
dyskinesia I-OSE_Labeled_AE
is O
a O
syndrome O
consisting O
of O
potentially O
irreversible O
, O
involuntary O
, O
dyskinetic B-NonOSE_AE
movements I-NonOSE_AE
that O
can O
develop O
in O
patients O
treated O
with O
antipsychotic O
drugs O
. O

Although O
the O
prevalence O
of O
the O
syndrome O
appears O
to O
be O
highest O
among O
the O
elderly O
, O
especially O
elderly O
women O
, O
it O
is O
impossible O
to O
rely O
upon O
prevalence O
estimates O
to O
predict O
, O
at O
the O
inception O
of O
antipsychotic O
treatment O
, O
which O
patients O
are O
likely O
to O
develop O
the O
syndrome O
. O

Whether O
antipsychotic O
drug O
products O
differ O
in O
their O
potential O
to O
cause O
tardive B-NonOSE_AE
dyskinesia I-NonOSE_AE
is O
unknown O
. O

The O
risk O
of O
developing O
tardive B-NonOSE_AE
dyskinesia I-NonOSE_AE
and O
the O
likelihood O
that O
it O
will O
become O
irreversible O
are O
believed O
to O
increase O
as O
the O
duration O
of O
treatment O
and O
the O
total O
cumulative O
dose O
of O
antipsychotic O
drugs O
administered O
to O
the O
patient O
increase O
. O

However O
, O
the O
syndrome O
can O
develop O
, O
although O
much O
less O
commonly O
, O
after O
relatively O
brief O
treatment O
periods O
at O
low O
doses O
. O

There O
is O
no O
known O
treatment O
for O
established O
cases O
of O
tardive B-NonOSE_AE
dyskinesia I-NonOSE_AE
, O
although O
the O
syndrome O
may O
remit O
, O
partially O
or O
completely O
, O
if O
antipsychotic O
treatment O
is O
withdrawn O
. O

Antipsychotic O
treatment O
, O
itself O
, O
however O
, O
may O
suppress O
( O
or O
partially O
suppress O
) O
the O
signs O
and O
symptoms O
of O
the O
syndrome O
and O
thereby O
may O
possibly O
mask O
the O
underlying O
process O
. O

The O
effect O
that O
symptomatic O
suppression O
has O
upon O
the O
long-term O
course O
of O
the O
syndrome O
is O
unknown O
. O

Given O
these O
considerations O
, O
LATUDA O
should O
be O
prescribed O
in O
a O
manner O
that O
is O
most O
likely O
to O
minimize O
the O
occurrence O
of O
tardive B-NonOSE_AE
dyskinesia I-NonOSE_AE
. O

Chronic O
antipsychotic O
treatment O
should O
generally O
be O
reserved O
for O
patients O
who O
suffer O
from O
a O
chronic O
illness O
that O
( O
1 O
) O
is O
known O
to O
respond O
to O
antipsychotic O
drugs O
, O
and O
( O
2 O
) O
for O
whom O
alternative O
, O
equally O
effective O
, O
but O
potentially O
less O
harmful O
treatments O
are O
not O
available O
or O
appropriate O
. O

In O
patients O
who O
do O
require O
chronic O
treatment O
, O
the O
smallest O
dose O
and O
the O
shortest O
duration O
of O
treatment O
producing O
a O
satisfactory O
clinical O
response O
should O
be O
sought O
. O

The O
need O
for O
continued O
treatment O
should O
be O
reassessed O
periodically O
. O

If O
signs O
and O
symptoms O
of O
tardive B-NonOSE_AE
dyskinesia I-NonOSE_AE
appear O
in O
a O
patient O
on O
LATUDA O
, O
drug O
discontinuation O
should O
be O
considered O
. O

However O
, O
some O
patients O
may O
require O
treatment O
with O
LATUDA O
despite O
the O
presence O
of O
the O
syndrome O
. O

5.6 O
Metabolic O
Changes O
Atypical O
antipsychotic O
drugs O
have O
been O
associated O
with O
metabolic B-OSE_Labeled_AE
changes I-OSE_Labeled_AE
that O
may O
increase O
cardiovascular/cerebrovascular O
risk O
. O

These O
metabolic O
changes O
include O
hyperglycemia B-OSE_Labeled_AE
, O
dyslipidemia B-OSE_Labeled_AE
, O
and O
body B-OSE_Labeled_AE
weight I-OSE_Labeled_AE
gain I-OSE_Labeled_AE
. O

While O
all O
of O
the O
drugs O
in O
the O
class O
have O
been O
shown O
to O
produce O
some O
metabolic B-OSE_Labeled_AE
changes I-OSE_Labeled_AE
, O
each O
drug O
has O
its O
own O
specific O
risk O
profile O
. O

Hyperglycemia O
and O
Diabetes O
Mellitus O
Hyperglycemia B-OSE_Labeled_AE
, O
in O
some O
cases O
extreme O
and O
associated O
with O
ketoacidosis B-OSE_Labeled_AE
or O
hyperosmolar B-OSE_Labeled_AE
coma I-OSE_Labeled_AE
or O
death B-NonOSE_AE
, O
has O
been O
reported O
in O
patients O
treated O
with O
atypical O
antipsychotics O
. O

Assessment O
of O
the O
relationship O
between O
atypical O
antipsychotic O
use O
and O
glucose B-NonOSE_AE
abnormalities I-NonOSE_AE
is O
complicated O
by O
the O
possibility O
of O
an O
increased O
background O
risk O
of O
diabetes B-Not_AE_Candidate
mellitus I-Not_AE_Candidate
in O
patients O
with O
schizophrenia B-Not_AE_Candidate
and O
the O
increasing O
incidence O
of O
diabetes B-Not_AE_Candidate
mellitus I-Not_AE_Candidate
in O
the O
general O
population O
. O

Given O
these O
confounders O
, O
the O
relationship O
between O
atypical O
antipsychotic O
use O
and O
hyperglycemia B-NonOSE_AE
- I-NonOSE_AE
related I-NonOSE_AE
adverse I-NonOSE_AE
events I-NonOSE_AE
is O
not O
completely O
understood O
. O

However O
, O
epidemiological O
studies O
suggest O
an O
increased O
risk O
of O
treatment-emergent O
hyperglycemia B-OSE_Labeled_AE
- I-OSE_Labeled_AE
related I-OSE_Labeled_AE
adverse I-OSE_Labeled_AE
events I-OSE_Labeled_AE
in O
patients O
treated O
with O
the O
atypical O
antipsychotics O
. O

Because O
LATUDA O
was O
not O
marketed O
at O
the O
time O
these O
studies O
were O
performed O
, O
it O
is O
not O
known O
if O
LATUDA O
is O
associated O
with O
this O
increased O
risk O
. O

Patients O
with O
an O
established O
diagnosis O
of O
diabetes B-Not_AE_Candidate
mellitus I-Not_AE_Candidate
who O
are O
started O
on O
atypical O
antipsychotics O
should O
be O
monitored O
regularly O
for O
worsening B-NonOSE_AE
of I-NonOSE_AE
glucose I-NonOSE_AE
control I-NonOSE_AE
. O

Patients O
with O
risk O
factors O
for O
diabetes B-Not_AE_Candidate
mellitus I-Not_AE_Candidate
( O
e.g. O
, O
obesity B-Not_AE_Candidate
, O
family B-Not_AE_Candidate
history I-Not_AE_Candidate
of I-Not_AE_Candidate
diabetes I-Not_AE_Candidate
) O
who O
are O
starting O
treatment O
with O
atypical O
antipsychotics O
should O
undergo O
fasting O
blood O
glucose O
testing O
at O
the O
beginning O
of O
treatment O
and O
periodically O
during O
treatment O
. O

Any O
patient O
treated O
with O
atypical O
antipsychotics O
should O
be O
monitored O
for O
symptoms O
of O
hyperglycemia B-NonOSE_AE
including O
polydipsia B-NonOSE_AE
, O
polyuria B-NonOSE_AE
, O
polyphagia B-NonOSE_AE
, O
and O
weakness B-NonOSE_AE
. O

Patients O
who O
develop O
symptoms O
of O
hyperglycemia B-NonOSE_AE
during O
treatment O
with O
atypical O
antipsychotics O
should O
undergo O
fasting O
blood O
glucose O
testing O
. O

In O
some O
cases O
, O
hyperglycemia B-NonOSE_AE
has O
resolved O
when O
the O
atypical O
antipsychotic O
was O
discontinued O
; O
however O
, O
some O
patients O
required O
continuation O
of O
anti-diabetic O
treatment O
despite O
discontinuation O
of O
the O
suspect O
drug O
. O

Schizophrenia O
Pooled O
data O
from O
short-term O
, O
placebo-controlled O
schizophrenia B-Not_AE_Candidate
studies O
are O
presented O
in O
Table O
3 O
. O

Table O
3 O
: O
Change O
in O
Fasting O
Glucose O
in O
Schizophrenia O
Studies O
LATUDA O
Placebo O
20 O
mg/day O
40 O
mg/day O
80 O
mg/day O
120 O
mg/day O
160 O
mg/day O
Mean B-OSE_Labeled_AE
Change I-OSE_Labeled_AE
from I-OSE_Labeled_AE
Baseline I-OSE_Labeled_AE
( O
mg/dL O
) O
n=680 O
n=71 O
n=478 O
n=508 O
n=283 O
n=113 O
Serum I-OSE_Labeled_AE
Glucose I-OSE_Labeled_AE
-0.0 O
-0.6 O
+2.6 O
-0.4 O
+2.5 O
+ O
2.5 O
Proportion O
of O
Patients O
with O
Shifts O
to O
> O
= O
126 O
mg/dL O
Serum B-OSE_Labeled_AE
Glucose I-OSE_Labeled_AE
( I-OSE_Labeled_AE
> I-OSE_Labeled_AE
= I-OSE_Labeled_AE
1 I-OSE_Labeled_AE
2 I-OSE_Labeled_AE
6 I-OSE_Labeled_AE
mg I-OSE_Labeled_AE
/ I-OSE_Labeled_AE
dL I-OSE_Labeled_AE
) O
8.3 O
% O
( O
52/628 O
) O
11.7 O
% O
( O
7/60 O
) O
12.7 O
% O
( O
57/449 O
) O
6.8 O
% O
( O
32/472 O
) O
10.0 O
% O
( O
26/260 O
) O
5.6 O
% O
( O
6/108 O
) O
In O
the O
uncontrolled O
, O
longer-term O
schizophrenia B-Not_AE_Candidate
studies O
( O
primarily O
open-label O
extension O
studies O
) O
, O
LATUDA O
was O
associated O
with O
a O
mean B-OSE_Labeled_AE
change I-OSE_Labeled_AE
in I-OSE_Labeled_AE
glucose I-OSE_Labeled_AE
of O
+1.8 O
mg/dL O
at O
week O
24 O
( O
n=355 O
) O
, O
+0.8 O
mg/dL O
at O
week O
36 O
( O
n=299 O
) O
and O
+2.3 O
mg/dL O
at O
week O
52 O
( O
n=307 O
) O
. O

Bipolar O
Depression O
Monotherapy O
Data O
from O
the O
short-term O
, O
flexible-dose O
, O
placebo-controlled O
monotherapy O
bipolar B-Not_AE_Candidate
depression I-Not_AE_Candidate
study O
are O
presented O
in O
Table O
4 O
. O

Table O
4 O
: O
Change O
in O
Fasting O
Glucose O
in O
the O
Monotherapy O
Bipolar O
Depression O
Study O
LATUDA O
Placebo O
20 O
to O
60 O
mg/day O
80 O
to O
120 O
mg/day O
Mean B-OSE_Labeled_AE
Change I-OSE_Labeled_AE
from I-OSE_Labeled_AE
Baseline I-OSE_Labeled_AE
( O
mg/dL O
) O
Patients O
were O
randomized O
to O
flexibly O
dosed O
LATUDA O
20 O
to O
60 O
mg/day O
, O
LATUDA O
80 O
to O
120 O
mg/day O
, O
or O
placebo O
n=148 O
n=140 O
n=143 O
Serum I-OSE_Labeled_AE
Glucose I-OSE_Labeled_AE
+1.8 O
-0.8 O
+1.8 O
Proportion O
of O
Patients O
with O
Shifts O
to O
> O
= O
126 O
mg/dL O
Serum B-OSE_Labeled_AE
Glucose I-OSE_Labeled_AE
( I-OSE_Labeled_AE
> I-OSE_Labeled_AE
= I-OSE_Labeled_AE
1 I-OSE_Labeled_AE
2 I-OSE_Labeled_AE
6 I-OSE_Labeled_AE
mg I-OSE_Labeled_AE
/ I-OSE_Labeled_AE
dL I-OSE_Labeled_AE
) O
4.3 O
% O
( O
6/141 O
) O
2.2 O
% O
( O
3/138 O
) O
6.4 O
% O
( O
9/141 O
) O
In O
the O
uncontrolled O
, O
open-label O
, O
longer-term O
bipolar B-Not_AE_Candidate
depression I-Not_AE_Candidate
study O
, O
patients O
who O
received O
LATUDA O
as O
monotherapy O
in O
the O
short-term O
study O
and O
continued O
in O
the O
longer-term O
study O
, O
had O
a O
mean B-OSE_Labeled_AE
change I-OSE_Labeled_AE
in I-OSE_Labeled_AE
glucose I-OSE_Labeled_AE
of O
+1.2 O
mg/dL O
at O
week O
24 O
( O
n=129 O
) O
. O

Adjunctive O
Therapy O
with O
Lithium O
or O
Valproate O
Data O
from O
the O
short-term O
, O
flexible-dosed O
, O
placebo-controlled O
adjunctive O
therapy O
bipolar B-Not_AE_Candidate
depression I-Not_AE_Candidate
studies O
are O
presented O
in O
Table O
5 O
. O

Table O
5 O
: O
Change O
in O
Fasting O
Glucose O
in O
the O
Adjunctive O
Therapy O
Bipolar O
Depression O
Studies O
LATUDA O
Placebo O
20 O
to O
120 O
mg/day O
Mean B-OSE_Labeled_AE
Change I-OSE_Labeled_AE
from I-OSE_Labeled_AE
Baseline I-OSE_Labeled_AE
( O
mg/dL O
) O
Patients O
were O
randomized O
to O
flexibly O
dosed O
LATUDA O
20 O
to O
120 O
mg/day O
or O
placebo O
as O
adjunctive O
therapy O
with O
lithium O
or O
valproate O
. O

n=302 O
n=319 O
Serum I-OSE_Labeled_AE
Glucose I-OSE_Labeled_AE
-0.9 O
+1.2 O
Proportion O
of O
Patients O
with O
Shifts O
to O
> O
= O
126 O
mg/dL O
Serum B-OSE_Labeled_AE
Glucose I-OSE_Labeled_AE
( I-OSE_Labeled_AE
> I-OSE_Labeled_AE
= I-OSE_Labeled_AE
1 I-OSE_Labeled_AE
2 I-OSE_Labeled_AE
6 I-OSE_Labeled_AE
mg I-OSE_Labeled_AE
/ I-OSE_Labeled_AE
dL I-OSE_Labeled_AE
) O
1.0 O
% O
( O
3/290 O
) O
1.3 O
% O
( O
4/316 O
) O
In O
the O
uncontrolled O
, O
open-label O
, O
longer-term O
bipolar B-Not_AE_Candidate
depression I-Not_AE_Candidate
study O
, O
patients O
who O
received O
LATUDA O
as O
adjunctive O
therapy O
with O
either O
lithium O
or O
valproate O
in O
the O
short-term O
study O
and O
continued O
in O
the O
longer-term O
study O
, O
had O
a O
mean B-OSE_Labeled_AE
change I-OSE_Labeled_AE
in I-OSE_Labeled_AE
glucose I-OSE_Labeled_AE
of I-OSE_Labeled_AE
+ I-OSE_Labeled_AE
1 I-OSE_Labeled_AE
. I-OSE_Labeled_AE
7 I-OSE_Labeled_AE
mg I-OSE_Labeled_AE
/ I-OSE_Labeled_AE
dL I-OSE_Labeled_AE
at I-OSE_Labeled_AE
week I-OSE_Labeled_AE
2 I-OSE_Labeled_AE
4 I-OSE_Labeled_AE
( O
n=88 O
) O
. O

Dyslipidemia B-OSE_Labeled_AE
Undesirable B-OSE_Labeled_AE
alterations I-OSE_Labeled_AE
in I-OSE_Labeled_AE
lipids I-OSE_Labeled_AE
have O
been O
observed O
in O
patients O
treated O
with O
atypical O
antipsychotics O
. O

Schizophrenia O
Pooled O
data O
from O
short-term O
, O
placebo-controlled O
schizophrenia B-Not_AE_Candidate
studies O
are O
presented O
in O
Table O
6 O
. O

Table O
6 O
: O
Change O
in O
Fasting O
Lipids O
in O
Schizophrenia O
Studies O
LATUDA O
Placebo O
20 O
mg/day O
40 O
mg/day O
80 O
mg/day O
120 O
mg/day O
160 O
mg/day O
Mean B-OSE_Labeled_AE
Change I-OSE_Labeled_AE
from I-OSE_Labeled_AE
Baseline I-OSE_Labeled_AE
( O
mg/dL O
) O
n=660 O
n=71 O
n=466 O
n=499 O
n=268 O
n=115 O
Total I-OSE_Labeled_AE
Cholesterol I-OSE_Labeled_AE
-5.8 O
-12.3 O
-5.7 O
-6.2 O
-3.8 O
-6.9 O
Triglycerides O
-13.4 O
-29.1 O
-5.1 O
-13.0 O
-3.1 O
-10.6 O
Proportion O
of O
Patients O
with O
Shifts O
Total B-OSE_Labeled_AE
Cholesterol I-OSE_Labeled_AE
( I-OSE_Labeled_AE
> I-OSE_Labeled_AE
= I-OSE_Labeled_AE
2 I-OSE_Labeled_AE
4 I-OSE_Labeled_AE
0 I-OSE_Labeled_AE
mg I-OSE_Labeled_AE
/ I-OSE_Labeled_AE
dL I-OSE_Labeled_AE
) O
5.3 O
% O
( O
30/571 O
) O
13.8 O
% O
( O
8/58 O
) O
6.2 O
% O
( O
25/402 O
) O
5.3 O
% O
( O
23/434 O
) O
3.8 O
% O
( O
9/238 O
) O
4.0 O
% O
( O
4/101 O
) O
Triglycerides B-OSE_Labeled_AE
( I-OSE_Labeled_AE
> I-OSE_Labeled_AE
= I-OSE_Labeled_AE
2 I-OSE_Labeled_AE
0 I-OSE_Labeled_AE
0 I-OSE_Labeled_AE
mg I-OSE_Labeled_AE
/ I-OSE_Labeled_AE
dL I-OSE_Labeled_AE
) O
10.1 O
% O
( O
53/526 O
) O
14.3 O
% O
( O
7/49 O
) O
10.8 O
% O
( O
41/379 O
) O
6.3 O
% O
( O
25/400 O
) O
10.5 O
% O
( O
22/209 O
) O
7.0 O
% O
( O
7/100 O
) O
In O
the O
uncontrolled O
, O
longer-term O
schizophrenia B-Not_AE_Candidate
studies O
( O
primarily O
open-label O
extension O
studies O
) O
, O
LATUDA O
was O
associated O
with O
a O
mean B-OSE_Labeled_AE
change I-OSE_Labeled_AE
in I-OSE_Labeled_AE
total I-OSE_Labeled_AE
cholesterol I-OSE_Labeled_AE
and O
triglycerides O
of O
-3.8 O
( O
n=356 O
) O
and O
-15.1 O
( O
n=357 O
) O
mg/dL O
at O
week O
24 O
, O
-3.1 O
( O
n=303 O
) O
and O
-4.8 O
( O
n=303 O
) O
mg/dL O
at O
week O
36 O
and O
-2.5 O
( O
n=307 O
) O
and O
-6.9 O
( O
n=307 O
) O
mg/dL O
at O
week O
52 O
, O
respectively O
. O

Bipolar O
Depression O
Monotherapy O
Data O
from O
the O
short-term O
, O
flexible-dosed O
, O
placebo-controlled O
, O
monotherapy O
bipolar B-Not_AE_Candidate
depression I-Not_AE_Candidate
study O
are O
presented O
in O
Table O
7 O
. O

Table O
7 O
: O
Change O
in O
Fasting O
Lipids O
in O
the O
Monotherapy O
Bipolar O
Depression O
Study O
LATUDA O
Placebo O
20 O
to O
60 O
mg/day O
80 O
to O
120 O
mg/day O
Mean B-OSE_Labeled_AE
Change I-OSE_Labeled_AE
from I-OSE_Labeled_AE
Baseline I-OSE_Labeled_AE
( O
mg/dL O
) O
Patients O
were O
randomized O
to O
flexibly O
dosed O
LATUDA O
20 O
to O
60 O
mg/day O
, O
LATUDA O
80 O
to O
120 O
mg/day O
, O
or O
placebo O
n=147 O
n=140 O
n=144 O
Total I-OSE_Labeled_AE
cholesterol I-OSE_Labeled_AE
-3.2 O
+1.2 O
-4.6 O
Triglycerides O
+6.0 O
+5.6 O
+0.4 O
Proportion O
of O
Patients O
with O
Shifts O
Total B-OSE_Labeled_AE
cholesterol I-OSE_Labeled_AE
( I-OSE_Labeled_AE
> I-OSE_Labeled_AE
= I-OSE_Labeled_AE
2 I-OSE_Labeled_AE
4 I-OSE_Labeled_AE
0 I-OSE_Labeled_AE
mg I-OSE_Labeled_AE
/ I-OSE_Labeled_AE
dL I-OSE_Labeled_AE
) O
4.2 O
% O
( O
5/118 O
) O
4.4 O
% O
( O
5/113 O
) O
4.4 O
% O
( O
5/114 O
) O
Triglycerides B-OSE_Labeled_AE
( I-OSE_Labeled_AE
> I-OSE_Labeled_AE
= I-OSE_Labeled_AE
2 I-OSE_Labeled_AE
0 I-OSE_Labeled_AE
0 I-OSE_Labeled_AE
mg I-OSE_Labeled_AE
/ I-OSE_Labeled_AE
dL I-OSE_Labeled_AE
) O
4.8 O
% O
( O
6/126 O
) O
10.1 O
% O
( O
12/119 O
) O
9.8 O
% O
( O
12/122 O
) O
In O
the O
uncontrolled O
, O
open-label O
, O
longer-term O
bipolar B-Not_AE_Candidate
depression I-Not_AE_Candidate
study O
, O
patients O
who O
received O
LATUDA O
as O
monotherapy O
in O
the O
short-term O
and O
continued O
in O
the O
longer-term O
study O
had O
a O
mean B-OSE_Labeled_AE
change I-OSE_Labeled_AE
in I-OSE_Labeled_AE
total I-OSE_Labeled_AE
cholesterol I-OSE_Labeled_AE
and O
triglycerides O
of O
-0.5 O
( O
n=130 O
) O
and O
-1.0 O
( O
n=130 O
) O
mg/dL O
at O
week O
24 O
, O
respectively O
. O

Adjunctive O
Therapy O
with O
Lithium O
or O
Valproate O
Data O
from O
the O
short-term O
, O
flexible-dosed O
, O
placebo-controlled O
, O
adjunctive O
therapy O
bipolar B-Not_AE_Candidate
depression I-Not_AE_Candidate
studies O
are O
presented O
in O
Table O
8 O
. O

Table O
8 O
: O
Change O
in O
Fasting O
Lipids O
in O
the O
Adjunctive O
Therapy O
Bipolar O
Depression O
Studies O
LATUDA O
Placebo O
20 O
to O
120 O
mg/day O
Mean B-OSE_Labeled_AE
Change I-OSE_Labeled_AE
from I-OSE_Labeled_AE
Baseline I-OSE_Labeled_AE
( O
mg/dL O
) O
Patients O
were O
randomized O
to O
flexibly O
dosed O
LATUDA O
20 O
to O
120 O
mg/day O
or O
placebo O
as O
adjunctive O
therapy O
with O
lithium O
or O
valproate O
. O

n=303 O
n=321 O
Total I-OSE_Labeled_AE
cholesterol I-OSE_Labeled_AE
-2.9 O
-3.1 O
Triglycerides O
-4.6 O
+4.6 O
Proportion O
of O
Patients O
with O
Shifts O
Total B-OSE_Labeled_AE
cholesterol I-OSE_Labeled_AE
( I-OSE_Labeled_AE
> I-OSE_Labeled_AE
= I-OSE_Labeled_AE
2 I-OSE_Labeled_AE
4 I-OSE_Labeled_AE
0 I-OSE_Labeled_AE
mg I-OSE_Labeled_AE
/ I-OSE_Labeled_AE
dL I-OSE_Labeled_AE
) O
5.7 O
% O
( O
15/263 O
) O
5.4 O
% O
( O
15/276 O
) O
Triglycerides B-OSE_Labeled_AE
( I-OSE_Labeled_AE
> I-OSE_Labeled_AE
= I-OSE_Labeled_AE
2 I-OSE_Labeled_AE
0 I-OSE_Labeled_AE
0 I-OSE_Labeled_AE
mg I-OSE_Labeled_AE
/ I-OSE_Labeled_AE
dL I-OSE_Labeled_AE
) O
8.6 O
% O
( O
21/243 O
) O
10.8 O
% O
( O
28/260 O
) O
In O
the O
uncontrolled O
, O
open-label O
, O
longer-term O
bipolar B-Not_AE_Candidate
depression I-Not_AE_Candidate
study O
, O
patients O
who O
received O
LATUDA O
, O
as O
adjunctive O
therapy O
with O
either O
lithium O
or O
valproate O
in O
the O
short-term O
study O
and O
continued O
in O
the O
longer-term O
study O
, O
had O
a O
mean B-OSE_Labeled_AE
change I-OSE_Labeled_AE
in I-OSE_Labeled_AE
total I-OSE_Labeled_AE
cholesterol I-OSE_Labeled_AE
and O
triglycerides O
of O
-0.9 O
( O
n=88 O
) O
and O
+5.3 O
( O
n=88 O
) O
mg/dL O
at O
week O
24 O
, O
respectively O
. O

Weight O
Gain O
Weight B-OSE_Labeled_AE
gain I-OSE_Labeled_AE
has O
been O
observed O
with O
atypical O
antipsychotic O
use O
. O

Clinical O
monitoring O
of O
weight O
is O
recommended O
. O

Schizophrenia O
Pooled O
data O
from O
short-term O
, O
placebo-controlled O
schizophrenia O
studies O
are O
presented O
in O
Table O
9 O
. O

The O
mean O
weight B-OSE_Labeled_AE
gain I-OSE_Labeled_AE
was O
+0.43 O
kg O
for O
LATUDA-treated O
patients O
compared O
to O
-0.02 O
kg O
for O
placebo-treated O
patients O
. O

Change B-NonOSE_AE
in I-NonOSE_AE
weight I-NonOSE_AE
from I-NonOSE_AE
baseline I-NonOSE_AE
for O
olanzapine O
was O
+4.15 O
kg O
and O
for O
quetiapine O
extended-release O
was O
+2.09 O
kg O
in O
Studies O
3 O
and O
5 O
[ O
see O
Clinical O
Studies O
( O
14.1 O
) O
] O
, O
respectively O
. O

The O
proportion O
of O
patients O
with O
a O
> O
= O
7 O
% O
increase B-OSE_Labeled_AE
in O
body I-OSE_Labeled_AE
weight I-OSE_Labeled_AE
( O
at O
Endpoint O
) O
was O
4.8 O
% O
for O
LATUDA-treated O
patients O
versus O
3.3 O
% O
for O
placebo-treated O
patients O
. O

Table O
9 O
: O
Mean B-OSE_Labeled_AE
Change I-OSE_Labeled_AE
in I-OSE_Labeled_AE
Weight I-OSE_Labeled_AE
( O
kg O
) O
from O
Baseline O
in O
Schizophrenia O
Studies O
LATUDA O
Placebo O
( O
n=696 O
) O
20 O
mg/day O
( O
n=71 O
) O
40 O
mg/day O
( O
n=484 O
) O
80 O
mg/day O
( O
n=526 O
) O
120 O
mg/day O
( O
n=291 O
) O
160 O
mg/day O
( O
n=114 O
) O
All O
Patients O
-0.02 O
-0.15 O
+0.22 O
+0.54 O
+0.68 O
+0.60 O
In O
the O
uncontrolled O
, O
longer-term O
schizophrenia B-Not_AE_Candidate
studies O
( O
primarily O
open-label O
extension O
studies O
) O
, O
LATUDA O
was O
associated O
with O
a O
mean B-OSE_Labeled_AE
change I-OSE_Labeled_AE
in I-OSE_Labeled_AE
weight I-OSE_Labeled_AE
of O
-0.69 O
kg O
at O
week O
24 O
( O
n=755 O
) O
, O
-0.59 O
kg O
at O
week O
36 O
( O
n=443 O
) O
and O
-0.73 O
kg O
at O
week O
52 O
( O
n=377 O
) O
. O

Bipolar O
Depression O
Monotherapy O
Data O
from O
the O
short-term O
, O
flexible-dosed O
, O
placebo-controlled O
monotherapy O
bipolar B-Not_AE_Candidate
depression I-Not_AE_Candidate
study O
are O
presented O
in O
Table O
10 O
. O

The O
mean O
weight B-OSE_Labeled_AE
gain I-OSE_Labeled_AE
was O
+0.29 O
kg O
for O
LATUDA-treated O
patients O
compared O
to O
-0.04 O
kg O
for O
placebo-treated O
patients O
. O

The O
proportion O
of O
patients O
with O
a O
> O
= O
7 O
% O
increase B-OSE_Labeled_AE
in O
body I-OSE_Labeled_AE
weight I-OSE_Labeled_AE
( O
at O
Endpoint O
) O
was O
2.4 O
% O
for O
LATUDA-treated O
patients O
versus O
0.7 O
% O
for O
placebo-treated O
patients O
. O

Table O
10 O
: O
Mean B-OSE_Labeled_AE
Change I-OSE_Labeled_AE
in I-OSE_Labeled_AE
Weight I-OSE_Labeled_AE
( O
kg O
) O
from O
Baseline O
in O
the O
Monotherapy O
Bipolar O
Depression O
Study O
LATUDA O
Placebo O
( O
n=151 O
) O
20 O
to O
60 O
mg/day O
( O
n=143 O
) O
80 O
to O
120 O
mg/day O
( O
n=147 O
) O
Patients O
were O
randomized O
to O
flexibly O
dosed O
LATUDA O
20 O
to O
60 O
mg/day O
, O
LATUDA O
80 O
to O
120 O
mg/day O
, O
or O
placebo O
All O
Patients O
-0.04 O
+0.56 O
+0.02 O
In O
the O
uncontrolled O
, O
open-label O
, O
longer-term O
bipolar B-Not_AE_Candidate
depression I-Not_AE_Candidate
study O
, O
patients O
who O
received O
LATUDA O
as O
monotherapy O
in O
the O
short-term O
and O
continued O
in O
the O
longer-term O
study O
had O
a O
mean B-OSE_Labeled_AE
change I-OSE_Labeled_AE
in I-OSE_Labeled_AE
weight I-OSE_Labeled_AE
of I-OSE_Labeled_AE
- I-OSE_Labeled_AE
0 I-OSE_Labeled_AE
. I-OSE_Labeled_AE
0 I-OSE_Labeled_AE
2 I-OSE_Labeled_AE
kg I-OSE_Labeled_AE
at O
week O
24 O
( O
n=130 O
) O
. O

Adjunctive O
Therapy O
with O
Lithium O
or O
Valproate O
Data O
from O
the O
short-term O
, O
flexible-dosed O
, O
placebo-controlled O
adjunctive O
therapy O
bipolar B-Not_AE_Candidate
depression I-Not_AE_Candidate
studies O
are O
presented O
in O
Table O
11 O
. O

The O
mean O
weight B-OSE_Labeled_AE
gain I-OSE_Labeled_AE
was O
+0.11 O
kg O
for O
LATUDA-treated O
patients O
compared O
to O
+0.16 O
kg O
for O
placebo-treated O
patients O
. O

The O
proportion O
of O
patients O
with O
a O
> O
= O
7 O
% O
increase B-OSE_Labeled_AE
in O
body I-OSE_Labeled_AE
weight I-OSE_Labeled_AE
( O
at O
Endpoint O
) O
was O
3.1 O
% O
for O
LATUDA-treated O
patients O
versus O
0.3 O
% O
for O
placebo-treated O
patients O
. O

Table O
11 O
: O
Mean B-OSE_Labeled_AE
Change I-OSE_Labeled_AE
in I-OSE_Labeled_AE
Weight I-OSE_Labeled_AE
( O
kg O
) O
from O
Baseline O
in O
the O
Adjunctive O
Therapy O
Bipolar O
Depression O
Studies O
LATUDA O
Placebo O
( O
n=307 O
) O
20 O
to O
120 O
mg/day O
( O
n=327 O
) O
Patients O
were O
randomized O
to O
flexibly O
dosed O
LATUDA O
20 O
to O
120 O
mg/day O
or O
placebo O
as O
adjunctive O
therapy O
with O
lithium O
or O
valproate O
. O

All O
Patients O
+0.16 O
+0.11 O
In O
the O
uncontrolled O
, O
open-label O
, O
longer-term O
bipolar B-Not_AE_Candidate
depression I-Not_AE_Candidate
study O
, O
patients O
who O
were O
treated O
with O
LATUDA O
, O
as O
adjunctive O
therapy O
with O
either O
lithium O
or O
valproate O
in O
the O
short-term O
and O
continued O
in O
the O
longer-term O
study O
, O
had O
a O
mean B-OSE_Labeled_AE
change I-OSE_Labeled_AE
in I-OSE_Labeled_AE
weight I-OSE_Labeled_AE
of O
+1.28 O
kg O
at O
week O
24 O
( O
n=86 O
) O
. O

5.7 O
Hyperprolactinemia B-OSE_Labeled_AE
As O
with O
other O
drugs O
that O
antagonize O
dopamine O
D2receptors O
, O
LATUDA O
elevates B-OSE_Labeled_AE
prolactin I-OSE_Labeled_AE
levels I-OSE_Labeled_AE
. O

Hyperprolactinemia B-NonOSE_AE
may O
suppress B-NonOSE_AE
hypothalamic I-NonOSE_AE
GnRH I-NonOSE_AE
, O
resulting O
in O
reduced B-NonOSE_AE
pituitary I-NonOSE_AE
gonadotrophin I-NonOSE_AE
secretion I-NonOSE_AE
. O

This O
, O
in O
turn O
, O
may O
inhibit B-NonOSE_AE
reproductive I-NonOSE_AE
function I-NonOSE_AE
by I-NonOSE_AE
impairing I-NonOSE_AE
gonadal I-NonOSE_AE
steroidogenesis I-NonOSE_AE
in O
both O
female O
and O
male O
patients O
. O

Galactorrhea B-OSE_Labeled_AE
, O
amenorrhea B-OSE_Labeled_AE
, O
gynecomastia B-OSE_Labeled_AE
, O
and O
impotence B-OSE_Labeled_AE
have O
been O
reported O
with O
prolactin-elevating O
compounds O
. O

Long-standing O
hyperprolactinemia B-NonOSE_AE
, O
when O
associated O
with O
hypogonadism B-NonOSE_AE
, O
may O
lead O
to O
decreased B-NonOSE_AE
bone I-NonOSE_AE
density I-NonOSE_AE
in O
both O
female O
and O
male O
patients O
[ O
see O
Adverse O
Reactions O
( O
6 O
) O
] O
. O

Tissue O
culture O
experiments O
indicate O
that O
approximately O
one-third O
of O
human O
breast B-NonOSE_AE
cancers I-NonOSE_AE
are O
prolactin-dependent O
in O
vitro O
, O
a O
factor O
of O
potential O
importance O
if O
the O
prescription O
of O
these O
drugs O
is O
considered O
in O
a O
patient O
with O
previously O
detected O
breast B-Not_AE_Candidate
cancer I-Not_AE_Candidate
. O

As O
is O
common O
with O
compounds O
which O
increase B-NonOSE_AE
prolactin I-NonOSE_AE
release I-NonOSE_AE
, O
an O
increase B-NonOSE_AE
in I-NonOSE_AE
mammary I-NonOSE_AE
gland I-NonOSE_AE
neoplasia I-NonOSE_AE
was O
observed O
in O
a O
LATUDA O
carcinogenicity B-NonOSE_AE
study O
conducted O
in O
rats O
and O
mice O
[ O
see O
Nonclinical O
Toxicology O
( O
13 O
) O
] O
. O

Neither O
clinical O
studies O
nor O
epidemiologic O
studies O
conducted O
to O
date O
have O
shown O
an O
association O
between O
chronic O
administration O
of O
this O
class O
of O
drugs O
and O
tumorigenesis B-NonOSE_AE
in O
humans O
, O
but O
the O
available O
evidence O
is O
too O
limited O
to O
be O
conclusive O
. O

Schizophrenia O
In O
short-term O
, O
placebo-controlled O
schizophrenia B-Not_AE_Candidate
studies O
, O
the O
median B-OSE_Labeled_AE
change I-OSE_Labeled_AE
from I-OSE_Labeled_AE
baseline I-OSE_Labeled_AE
to I-OSE_Labeled_AE
endpoint I-OSE_Labeled_AE
in I-OSE_Labeled_AE
prolactin I-OSE_Labeled_AE
levels I-OSE_Labeled_AE
for O
LATUDA-treated O
patients O
was O
+0.4 O
ng/mL O
and O
was O
-1.9 O
ng/mL O
in O
the O
placebo-treated O
patients O
. O

The O
median O
change O
from O
baseline O
to O
endpoint O
for O
males O
was O
+0.5 O
ng/mL O
and O
for O
females O
was O
-0.2 O
ng/mL O
. O

Median B-NonOSE_AE
changes I-NonOSE_AE
for I-NonOSE_AE
prolactin I-NonOSE_AE
by O
dose O
are O
shown O
in O
Table O
12 O
. O

Table O
12 O
: O
Median B-OSE_Labeled_AE
Change I-OSE_Labeled_AE
in I-OSE_Labeled_AE
Prolactin I-OSE_Labeled_AE
( I-OSE_Labeled_AE
ng I-OSE_Labeled_AE
/ I-OSE_Labeled_AE
mL I-OSE_Labeled_AE
) I-OSE_Labeled_AE
from I-OSE_Labeled_AE
Baseline I-OSE_Labeled_AE
in O
Schizophrenia O
Studies O
LATUDA O
Placebo O
20 O
mg/day O
40 O
mg/day O
80 O
mg/day O
120 O
mg/day O
160 O
mg/day O
All O
Patients O
-1.9 O
( O
n=672 O
) O
-1.1 O
( O
n=70 O
) O
-1.4 O
( O
n=476 O
) O
-0.2 O
( O
n=495 O
) O
+3.3 O
( O
n=284 O
) O
+3.3 O
( O
n=115 O
) O
Females O
-5.1 O
( O
n=200 O
) O
-0.7 O
( O
n=19 O
) O
-4.0 O
( O
n=149 O
) O
-0.2 O
( O
n=150 O
) O
+6.7 O
( O
n=70 O
) O
+7.1 O
( O
n=36 O
) O
Males O
-1.3 O
( O
n=472 O
) O
-1.2 O
( O
n=51 O
) O
-0.7 O
( O
n=327 O
) O
-0.2 O
( O
n=345 O
) O
+3.1 O
( O
n=214 O
) O
+2.4 O
( O
n=79 O
) O
The O
proportion O
of O
patients O
with O
prolactin B-OSE_Labeled_AE
elevations I-OSE_Labeled_AE
> O
= O
5* O
upper O
limit O
of O
normal O
( O
ULN O
) O
was O
2.8 O
% O
for O
LATUDA-treated O
patients O
versus O
1.0 O
% O
for O
placebo-treated O
patients O
. O

The O
proportion O
of O
female O
patients O
with O
prolactin B-OSE_Labeled_AE
elevations I-OSE_Labeled_AE
> O
= O
5x O
ULN O
was O
5.7 O
% O
for O
LATUDA-treated O
patients O
versus O
2.0 O
% O
for O
placebo-treated O
female O
patients O
. O

The O
proportion O
of O
male O
patients O
with O
prolactin B-OSE_Labeled_AE
elevations I-OSE_Labeled_AE
> O
= O
5x O
ULN O
was O
1.6 O
% O
versus O
0.6 O
% O
for O
placebo-treated O
male O
patients O
. O

In O
the O
uncontrolled O
longer-term O
schizophrenia B-Not_AE_Candidate
studies O
( O
primarily O
open-label O
extension O
studies O
) O
, O
LATUDA O
was O
associated O
with O
a O
median B-OSE_Labeled_AE
change I-OSE_Labeled_AE
in I-OSE_Labeled_AE
prolactin I-OSE_Labeled_AE
of O
-0.9 O
ng/mL O
at O
week O
24 O
( O
n=357 O
) O
, O
-5.3ng/mL O
at O
week O
36 O
( O
n=190 O
) O
and O
-2.2 O
ng/mL O
at O
week O
52 O
( O
n=307 O
) O
. O

Bipolar O
Depression O
Monotherapy O
The O
median B-OSE_Labeled_AE
change I-OSE_Labeled_AE
from I-OSE_Labeled_AE
baseline I-OSE_Labeled_AE
to O
endpoint O
in O
prolactin I-OSE_Labeled_AE
levels I-OSE_Labeled_AE
, O
in O
the O
short-term O
, O
flexible-dosed O
, O
placebo-controlled O
monotherapy O
bipolar B-Not_AE_Candidate
depression I-Not_AE_Candidate
study O
, O
was O
+1.7 O
ng/mL O
and O
+3.5 O
ng/mL O
with O
LATUDA O
20 O
to O
60 O
mg/day O
and O
80 O
to O
120 O
mg/day O
, O
respectively O
compared O
to O
+0.3 O
ng/mL O
with O
placebo-treated O
patients O
. O

The O
median O
change O
from O
baseline O
to O
endpoint O
for O
males O
was O
+1.5 O
ng/mL O
and O
for O
females O
was O
+3.1 O
ng/mL O
. O

Median B-NonOSE_AE
changes I-NonOSE_AE
for I-NonOSE_AE
prolactin I-NonOSE_AE
by O
dose O
range O
are O
shown O
in O
Table O
13 O
. O

Table O
13 O
: O
Median B-OSE_Labeled_AE
Change I-OSE_Labeled_AE
in I-OSE_Labeled_AE
Prolactin I-OSE_Labeled_AE
( O
ng/mL O
) O
from O
Baseline O
in O
the O
Monotherapy O
Bipolar O
Depression O
Study O
LATUDA O
Placebo O
20 O
to O
60 O
mg/day O
80 O
to O
120 O
mg/day O
Patients O
were O
randomized O
to O
flexibly O
dosed O
LATUDA O
20 O
to O
60 O
mg/day O
, O
LATUDA O
80 O
to O
120 O
mg/day O
, O
or O
placebo O
All O
Patients O
+0.3 O
( O
n=147 O
) O
+1.7 O
( O
n=140 O
) O
+3.5 O
( O
n=144 O
) O
Females O
0.0 O
( O
n=82 O
) O
+1.8 O
( O
n=78 O
) O
+5.3 O
( O
n=88 O
) O
Males O
+0.4 O
( O
n=65 O
) O
+1.2 O
( O
n=62 O
) O
+1.9 O
( O
n=56 O
) O
The O
proportion O
of O
patients O
with O
prolactin B-OSE_Labeled_AE
elevations I-OSE_Labeled_AE
> O
= O
5x O
upper O
limit O
of O
normal O
( O
ULN O
) O
was O
0.4 O
% O
for O
LATUDA-treated O
patients O
versus O
0.0 O
% O
for O
placebo-treated O
patients O
. O

The O
proportion O
of O
female O
patients O
with O
prolactin B-OSE_Labeled_AE
elevations I-OSE_Labeled_AE
> O
= O
5x O
ULN O
was O
0.6 O
% O
for O
LATUDA-treated O
patients O
versus O
0 O
% O
for O
placebo-treated O
female O
patients O
. O

The O
proportion O
of O
male O
patients O
with O
prolactin B-OSE_Labeled_AE
elevations I-OSE_Labeled_AE
> O
= O
5x O
ULN O
was O
0 O
% O
versus O
0 O
% O
for O
placebo-treated O
male O
patients O
. O

In O
the O
uncontrolled O
, O
open-label O
, O
longer-term O
bipolar B-Not_AE_Candidate
depression I-Not_AE_Candidate
study O
, O
patients O
who O
were O
treated O
with O
LATUDA O
as O
monotherapy O
in O
the O
short-term O
and O
continued O
in O
the O
longer-term O
study O
, O
had O
a O
median B-OSE_Labeled_AE
change I-OSE_Labeled_AE
in I-OSE_Labeled_AE
prolactin I-OSE_Labeled_AE
of O
-1.15 O
ng/mL O
at O
week O
24 O
( O
n=130 O
) O
. O

Adjunctive O
Therapy O
with O
Lithium O
or O
Valproate O
The O
median B-OSE_Labeled_AE
change I-OSE_Labeled_AE
from I-OSE_Labeled_AE
baseline I-OSE_Labeled_AE
to O
endpoint O
in O
prolactin I-OSE_Labeled_AE
levels I-OSE_Labeled_AE
, O
in O
the O
short-term O
, O
flexible-dosed O
, O
placebo-controlled O
adjunctive O
therapy O
bipolar B-Not_AE_Candidate
depression I-Not_AE_Candidate
studies O
was O
+2.8 O
ng/mL O
with O
LATUDA O
20 O
to O
120 O
mg/day O
compared O
to O
0.0 O
ng/mL O
with O
placebo-treated O
patients O
. O

The O
median O
change O
from O
baseline O
to O
endpoint O
for O
males O
was O
+2.4 O
ng/mL O
and O
for O
females O
was O
+3.2 O
ng/mL O
. O

Median O
changes O
for O
prolactin O
across O
the O
dose O
range O
are O
shown O
in O
Table O
14 O
. O

Table O
14 O
: O
Median B-OSE_Labeled_AE
Change I-OSE_Labeled_AE
in I-OSE_Labeled_AE
Prolactin I-OSE_Labeled_AE
( I-OSE_Labeled_AE
ng I-OSE_Labeled_AE
/ I-OSE_Labeled_AE
mL I-OSE_Labeled_AE
) I-OSE_Labeled_AE
from I-OSE_Labeled_AE
Baseline I-OSE_Labeled_AE
in O
the O
Adjunctive O
Therapy O
Bipolar O
Depression O
Studies O
LATUDA O
Placebo O
20 O
to O
120 O
mg/day O
Patients O
were O
randomized O
to O
flexibly O
dosed O
LATUDA O
20 O
to O
120 O
mg/day O
or O
placebo O
as O
adjunctive O
therapy O
with O
lithium O
or O
valproate O
. O

All O
Patients O
0.0 O
( O
n=301 O
) O
+2.8 O
( O
n=321 O
) O
Females O
+0.4 O
( O
n=156 O
) O
+3.2 O
( O
n=162 O
) O
Males O
-0.1 O
( O
n=145 O
) O
+2.4 O
( O
n=159 O
) O
The O
proportion O
of O
patients O
with O
prolactin B-NonOSE_AE
elevations I-NonOSE_AE
> O
= O
5x O
upper O
limit O
of O
normal O
( O
ULN O
) O
was O
0.0 O
% O
for O
LATUDA-treated O
patients O
versus O
0.0 O
% O
for O
placebo-treated O
patients O
. O

The O
proportion O
of O
female O
patients O
with O
prolactin B-NonOSE_AE
elevations I-NonOSE_AE
> O
= O
5x O
ULN O
was O
0 O
% O
for O
LATUDA-treated O
patients O
versus O
0 O
% O
for O
placebo-treated O
female O
patients O
. O

The O
proportion O
of O
male O
patients O
with O
prolactin B-NonOSE_AE
elevations I-NonOSE_AE
> O
= O
5x O
ULN O
was O
0 O
% O
versus O
0 O
% O
for O
placebo-treated O
male O
patients O
. O

In O
the O
uncontrolled O
, O
open-label O
, O
longer-term O
bipolar B-Not_AE_Candidate
depression I-Not_AE_Candidate
study O
, O
patients O
who O
were O
treated O
with O
LATUDA O
, O
as O
adjunctive O
therapy O
with O
either O
lithium O
or O
valproate O
, O
in O
the O
short-term O
and O
continued O
in O
the O
longer-term O
study O
, O
had O
a O
median B-OSE_Labeled_AE
change I-OSE_Labeled_AE
in I-OSE_Labeled_AE
prolactin I-OSE_Labeled_AE
of O
-2.9 O
ng/mL O
at O
week O
24 O
( O
n=88 O
) O
. O

5.8 O
Leukopenia O
, O
Neutropenia O
and O
Agranulocytosis O
Leukopenia B-OSE_Labeled_AE
/ O
neutropenia B-OSE_Labeled_AE
has O
been O
reported O
during O
treatment O
with O
antipsychotic O
agents O
. O

Agranulocytosis B-NonOSE_AE
( O
including O
fatal B-NonOSE_AE
cases O
) O
has O
been O
reported O
with O
other O
agents O
in O
the O
class O
. O

Possible O
risk O
factors O
for O
leukopenia B-NonOSE_AE
/ O
neutropenia B-NonOSE_AE
include O
pre-existing O
low B-Not_AE_Candidate
white I-Not_AE_Candidate
blood I-Not_AE_Candidate
cell I-Not_AE_Candidate
count I-Not_AE_Candidate
( I-Not_AE_Candidate
WBC I-Not_AE_Candidate
) O
and O
history O
of O
drug B-Not_AE_Candidate
- I-Not_AE_Candidate
induced I-Not_AE_Candidate
leukopenia I-Not_AE_Candidate
/neutropenia O
. O

Patients O
with O
a O
pre-existing O
low B-Not_AE_Candidate
WBC I-Not_AE_Candidate
or O
a O
history O
of O
drug B-Not_AE_Candidate
- I-Not_AE_Candidate
induced I-Not_AE_Candidate
leukopenia I-Not_AE_Candidate
/neutropenia O
should O
have O
their O
complete O
blood O
count O
( O
CBC O
) O
monitored O
frequently O
during O
the O
first O
few O
months O
of O
therapy O
and O
LATUDA O
should O
be O
discontinued O
at O
the O
first O
sign O
of O
decline B-NonOSE_AE
in I-NonOSE_AE
WBC I-NonOSE_AE
, O
in O
the O
absence O
of O
other O
causative O
factors O
. O

Patients O
with O
neutropenia B-NonOSE_AE
should O
be O
carefully O
monitored O
for O
fever B-NonOSE_AE
or O
other O
symptoms O
or O
signs O
of O
infection B-NonOSE_AE
and O
treated O
promptly O
if O
such O
symptoms O
or O
signs O
occur O
. O

Patients O
with O
severe O
neutropenia B-NonOSE_AE
( O
absolute B-NonOSE_AE
neutrophil I-NonOSE_AE
count I-NonOSE_AE
< I-NonOSE_AE
1 I-NonOSE_AE
0 I-NonOSE_AE
0 I-NonOSE_AE
0 I-NonOSE_AE
/ I-NonOSE_AE
mm I-NonOSE_AE
3 I-NonOSE_AE
) O
should O
discontinue O
LATUDA O
and O
have O
their O
WBC O
followed O
until O
recovery O
. O

5.9 O
Orthostatic O
Hypotension O
and O
Syncope O
LATUDA O
may O
cause O
orthostatic B-OSE_Labeled_AE
hypotension I-OSE_Labeled_AE
and O
syncope B-OSE_Labeled_AE
, O
perhaps O
due O
to O
its O
alpha1-adrenergic O
receptor O
antagonism O
. O

Associated O
adverse O
reactions O
can O
include O
dizziness B-OSE_Labeled_AE
, O
lightheadedness B-OSE_Labeled_AE
, O
tachycardia B-OSE_Labeled_AE
, O
and O
bradycardia B-OSE_Labeled_AE
. O

Generally O
, O
these O
risks O
are O
greatest O
at O
the O
beginning O
of O
treatment O
and O
during O
dose O
escalation O
. O

Patients O
at O
increased O
risk O
of O
these O
adverse O
reactions O
or O
at O
increased O
risk O
of O
developing O
complications O
from O
hypotension B-NonOSE_AE
include O
those O
with O
dehydration B-Not_AE_Candidate
, O
hypovolemia B-Not_AE_Candidate
, O
treatment O
with O
antihypertensive B-NonOSE_AE
medication I-NonOSE_AE
, O
history O
of O
cardiovascular B-Not_AE_Candidate
disease I-Not_AE_Candidate
( O
e.g. O
, O
heart B-Not_AE_Candidate
failure I-Not_AE_Candidate
, O
myocardial B-Not_AE_Candidate
infarction I-Not_AE_Candidate
, O
ischemia B-Not_AE_Candidate
, O
or O
conduction B-Not_AE_Candidate
abnormalities I-Not_AE_Candidate
) O
, O
history O
of O
cerebrovascular B-Not_AE_Candidate
disease I-Not_AE_Candidate
, O
as O
well O
as O
patients O
who O
are O
antipsychotic-naive O
. O

In O
such O
patients O
, O
consider O
using O
a O
lower O
starting O
dose O
and O
slower O
titration O
, O
and O
monitor O
orthostatic O
vital O
signs O
. O

Orthostatic B-NonOSE_AE
hypotension I-NonOSE_AE
, O
as O
assessed O
by O
vital O
sign O
measurement O
, O
was O
defined O
by O
the O
following O
vital O
sign O
changes O
: O
> O
= O
20 O
mm O
Hg O
decrease B-NonOSE_AE
in I-NonOSE_AE
systolic O
blood I-NonOSE_AE
pressure I-NonOSE_AE
and O
> O
= O
10 O
bpm O
increase B-NonOSE_AE
in I-NonOSE_AE
pulse I-NonOSE_AE
from O
sitting O
to O
standing O
or O
supine O
to O
standing O
position O
. O

Schizophrenia O
The O
incidence O
of O
orthostatic B-OSE_Labeled_AE
hypotension I-OSE_Labeled_AE
and O
syncope B-OSE_Labeled_AE
reported O
as O
adverse O
events O
from O
short-term O
, O
placebo-controlled O
schizophrenia B-Not_AE_Candidate
studies O
was O
( O
LATUDA O
incidence O
, O
placebo O
incidence O
) O
: O
orthostatic B-OSE_Labeled_AE
hypotension I-OSE_Labeled_AE
[ O
0.3 O
% O
( O
5/1508 O
) O
, O
0.1 O
% O
( O
1/708 O
) O
] O
and O
syncope B-OSE_Labeled_AE
[ O
0.1 O
% O
( O
2/1508 O
) O
, O
0 O
% O
( O
0/708 O
) O
] O
. O

In O
short-term O
schizophrenia B-Not_AE_Candidate
clinical O
studies O
, O
orthostatic B-OSE_Labeled_AE
hypotension I-OSE_Labeled_AE
, O
as O
assessed O
by O
vital O
signs O
, O
occurred O
with O
a O
frequency O
of O
0.8 O
% O
with O
LATUDA O
40 O
mg O
, O
2.1 O
% O
with O
LATUDA O
80 O
mg O
, O
1.7 O
% O
with O
LATUDA O
120 O
mg O
and O
0.8 O
% O
with O
LATUDA O
160 O
mg O
compared O
to O
0.7 O
% O
with O
placebo O
. O

Bipolar O
Depression O
Monotherapy O
In O
the O
short-term O
, O
flexible-dose O
, O
placebo-controlled O
monotherapy O
bipolar B-Not_AE_Candidate
depression I-Not_AE_Candidate
study O
, O
there O
were O
no O
reported O
adverse O
events O
of O
orthostatic B-NonOSE_AE
hypotension I-NonOSE_AE
and O
syncope B-NonOSE_AE
. O

Orthostatic B-OSE_Labeled_AE
hypotension I-OSE_Labeled_AE
, O
as O
assessed O
by O
vital O
signs O
, O
occurred O
with O
a O
frequency O
of O
0.6 O
% O
with O
LATUDA O
20 O
to O
60 O
mg O
and O
0.6 O
% O
with O
LATUDA O
80 O
to O
120 O
mg O
compared O
to O
0 O
% O
with O
placebo O
. O

Adjunctive O
Therapy O
with O
Lithium O
or O
Valproate O
In O
the O
short-term O
, O
flexible-dose O
, O
placebo-controlled O
adjunctive O
therapy O
bipolar B-Not_AE_Candidate
depression I-Not_AE_Candidate
therapy O
studies O
, O
there O
were O
no O
reported O
adverse O
events O
of O
orthostatic B-NonOSE_AE
hypotension I-NonOSE_AE
and O
syncope B-NonOSE_AE
. O

Orthostatic B-OSE_Labeled_AE
hypotension I-OSE_Labeled_AE
, O
as O
assessed O
by O
vital O
signs O
, O
occurred O
with O
a O
frequency O
of O
1.1 O
% O
with O
LATUDA O
20 O
to O
120 O
mg O
compared O
to O
0.9 O
% O
with O
placebo O
. O

5.10 O
Seizures O
As O
with O
other O
antipsychotic O
drugs O
, O
LATUDA O
should O
be O
used O
cautiously O
in O
patients O
with O
a O
history B-Not_AE_Candidate
of I-Not_AE_Candidate
seizures I-Not_AE_Candidate
or O
with O
conditions O
that O
lower B-NonOSE_AE
the I-NonOSE_AE
seizure I-NonOSE_AE
threshold I-NonOSE_AE
, O
e.g. O
, O
Alzheimer B-Not_AE_Candidate
' I-Not_AE_Candidate
s I-Not_AE_Candidate
dementia I-Not_AE_Candidate
. O

Conditions O
that O
lower B-NonOSE_AE
the I-NonOSE_AE
seizure I-NonOSE_AE
threshold I-NonOSE_AE
may O
be O
more O
prevalent O
in O
patients O
65 O
years O
or O
older O
. O

Schizophrenia O
In O
short-term O
, O
placebo-controlled O
schizophrenia B-Not_AE_Candidate
studies O
, O
seizures B-NonOSE_AE
/ O
convulsions B-NonOSE_AE
occurred O
in O
0.1 O
% O
( O
2/1508 O
) O
of O
patients O
treated O
with O
LATUDA O
compared O
to O
0.1 O
% O
( O
1/708 O
) O
placebo-treated O
patients O
. O

Bipolar O
Depression O
Monotherapy O
In O
the O
short-term O
, O
flexible-dose O
, O
placebo-controlled O
monotherapy O
bipolar B-Not_AE_Candidate
depression I-Not_AE_Candidate
study O
, O
no O
patient O
experienced O
seizures B-NonOSE_AE
/ O
convulsions B-NonOSE_AE
. O

Adjunctive O
Therapy O
with O
Lithium O
or O
Valproate O
In O
the O
short-term O
, O
flexible-dose O
, O
placebo-controlled O
adjunctive O
therapy O
bipolar B-Not_AE_Candidate
depression I-Not_AE_Candidate
studies O
, O
no O
patient O
experienced O
seizures B-NonOSE_AE
/ O
convulsions B-NonOSE_AE
. O

5.11 O
Potential O
for O
Cognitive B-OSE_Labeled_AE
and O
Motor O
Impairment I-OSE_Labeled_AE
LATUDA O
, O
like O
other O
antipsychotics O
, O
has O
the O
potential O
to O
impair B-OSE_Labeled_AE
judgment I-OSE_Labeled_AE
, O
thinking O
or O
motor O
skills O
. O

Caution O
patients O
about O
operating O
hazardous O
machinery O
, O
including O
motor O
vehicles O
, O
until O
they O
are O
reasonably O
certain O
that O
therapy O
with O
LATUDA O
does O
not O
affect O
them O
adversely O
. O

In O
clinical O
studies O
with O
LATUDA O
, O
somnolence B-OSE_Labeled_AE
included O
: O
hypersomnia B-OSE_Labeled_AE
, O
hypersomnolence B-OSE_Labeled_AE
, O
sedation B-OSE_Labeled_AE
and O
somnolence B-OSE_Labeled_AE
. O

Schizophrenia O
In O
short-term O
, O
placebo-controlled O
schizophrenia B-Not_AE_Candidate
studies O
, O
somnolence B-OSE_Labeled_AE
was O
reported O
by O
17.0 O
% O
( O
256/1508 O
) O
of O
patients O
treated O
with O
LATUDA O
( O
15.5 O
% O
LATUDA O
20 O
mg O
, O
15.6 O
% O
LATUDA O
40 O
mg O
, O
15.2 O
% O
LATUDA O
80 O
mg O
, O
26.5 O
% O
LATUDA O
120 O
mg O
and O
8.3 O
% O
LATUDA O
160 O
mg/day O
) O
compared O
to O
7.1 O
% O
( O
50/708 O
) O
of O
placebo O
patients O
. O

Bipolar O
Depression O
Monotherapy O
In O
the O
short-term O
, O
flexible-dosed O
, O
placebo-controlled O
monotherapy O
bipolar B-Not_AE_Candidate
depression I-Not_AE_Candidate
study O
, O
somnolence B-OSE_Labeled_AE
was O
reported O
by O
7.3 O
% O
( O
12/164 O
) O
and O
13.8 O
% O
( O
23/167 O
) O
with O
LATUDA O
20 O
to O
60 O
mg O
and O
80 O
to120 O
mg O
, O
respectively O
compared O
to O
6.5 O
% O
( O
11/168 O
) O
of O
placebo O
patients O
. O

Adjunctive O
Therapy O
with O
Lithium O
or O
Valproate O
In O
the O
short-term O
, O
flexible-dosed O
, O
placebo-controlled O
adjunctive O
therapy O
bipolar B-Not_AE_Candidate
depression I-Not_AE_Candidate
studies O
, O
somnolence B-OSE_Labeled_AE
was O
reported O
by O
11.4 O
% O
( O
41/360 O
) O
of O
patients O
treated O
with O
LATUDA O
20-120 O
mg O
compared O
to O
5.1 O
% O
( O
17/334 O
) O
of O
placebo O
patients O
. O

5.12 O
Body O
Temperature O
Dysregulation O
Disruption B-OSE_Labeled_AE
of I-OSE_Labeled_AE
the I-OSE_Labeled_AE
body I-OSE_Labeled_AE
' I-OSE_Labeled_AE
s I-OSE_Labeled_AE
ability I-OSE_Labeled_AE
to I-OSE_Labeled_AE
reduce I-OSE_Labeled_AE
core I-OSE_Labeled_AE
body I-OSE_Labeled_AE
temperature I-OSE_Labeled_AE
has O
been O
attributed O
to O
antipsychotic O
agents O
. O

Appropriate O
care O
is O
advised O
when O
prescribing O
LATUDA O
for O
patients O
who O
will O
be O
experiencing O
conditions O
that O
may O
contribute O
to O
an O
elevation B-NonOSE_AE
in I-NonOSE_AE
core I-NonOSE_AE
body I-NonOSE_AE
temperature I-NonOSE_AE
, O
e.g. O
, O
exercising O
strenuously O
, O
exposure O
to O
extreme O
heat O
, O
receiving O
concomitant O
medication O
with O
anticholinergic O
activity O
, O
or O
being O
subject O
to O
dehydration B-NonOSE_AE
[ O
see O
Patient O
Counseling O
Information O
( O
17.9 O
) O
] O
. O

5.13 O
Suicide O
The O
possibility O
of O
a O
suicide B-NonOSE_AE
attempt I-NonOSE_AE
is O
inherent O
in O
psychotic O
illness O
and O
close O
supervision O
of O
high-risk O
patients O
should O
accompany O
drug O
therapy O
. O

Prescriptions O
for O
LATUDA O
should O
be O
written O
for O
the O
smallest O
quantity O
of O
tablets O
consistent O
with O
good O
patient O
management O
in O
order O
to O
reduce O
the O
risk O
of O
overdose B-NonOSE_AE
. O

Schizophrenia O
In O
short-term O
, O
placebo-controlled O
schizophrenia B-Not_AE_Candidate
studies O
, O
the O
incidence O
of O
treatment-emergent O
suicidal B-NonOSE_AE
ideation I-NonOSE_AE
was O
0.4 O
% O
( O
6/1508 O
) O
for O
LATUDA-treated O
patients O
compared O
to O
0.8 O
% O
( O
6/708 O
) O
on O
placebo O
. O

No O
suicide B-NonOSE_AE
attempts I-NonOSE_AE
or O
completed B-NonOSE_AE
suicides I-NonOSE_AE
were O
reported O
in O
these O
studies O
. O

Bipolar O
Depression O
Monotherapy O
In O
the O
short-term O
, O
flexible-dose O
, O
placebo-controlled O
monotherapy O
bipolar B-Not_AE_Candidate
depression I-Not_AE_Candidate
study O
, O
the O
incidence O
of O
treatment-emergent O
suicidal B-NonOSE_AE
ideation I-NonOSE_AE
was O
0.0 O
% O
( O
0/331 O
) O
with O
LATUDA-treated O
patients O
compared O
to O
0.0 O
% O
( O
0/168 O
) O
with O
placebo-treated O
patients O
. O

No O
suicide B-NonOSE_AE
attempts I-NonOSE_AE
or O
completed B-NonOSE_AE
suicides I-NonOSE_AE
were O
reported O
in O
this O
study O
. O

Adjunctive O
Therapy O
with O
Lithium O
or O
Valproate O
In O
the O
short-term O
, O
flexible-dose O
, O
placebo-controlled O
adjunctive O
therapy O
bipolar B-Not_AE_Candidate
depression I-Not_AE_Candidate
studies O
, O
the O
incidence O
of O
treatment-emergent O
suicidal B-OSE_Labeled_AE
ideation I-OSE_Labeled_AE
was O
1.1 O
% O
( O
4/360 O
) O
for O
LATUDA-treated O
patients O
compared O
to O
0.3 O
% O
( O
1/334 O
) O
on O
placebo O
. O

No O
suicide B-NonOSE_AE
attempts I-NonOSE_AE
or O
completed B-NonOSE_AE
suicides I-NonOSE_AE
were O
reported O
in O
these O
studies O
. O

5.14 O
Activation O
of O
Mania/Hypomania O
Antidepressant O
treatment O
can O
increase O
the O
risk O
of O
developing O
a O
manic B-OSE_Labeled_AE
or O
hypomanic B-OSE_Labeled_AE
episode I-OSE_Labeled_AE
, O
particularly O
in O
patients O
with O
bipolar B-Not_AE_Candidate
disorder I-Not_AE_Candidate
. O

Monitor O
patients O
for O
the O
emergence O
of O
such O
episodes O
. O

In O
the O
bipolar B-Not_AE_Candidate
depression I-Not_AE_Candidate
monotherapy O
and O
adjunctive O
therapy O
( O
with O
lithium O
or O
valproate O
) O
studies O
, O
less O
than O
1 O
% O
of O
subjects O
in O
the O
LATUDA O
and O
placebo O
groups O
developed O
manic B-NonOSE_AE
or O
hypomanic B-NonOSE_AE
episodes I-NonOSE_AE
. O

5.15 O
Dysphagia B-OSE_Labeled_AE
Esophageal B-OSE_Labeled_AE
dysmotility I-OSE_Labeled_AE
and O
aspiration B-OSE_Labeled_AE
have O
been O
associated O
with O
antipsychotic O
drug O
use O
. O

Aspiration B-NonOSE_AE
pneumonia I-NonOSE_AE
is O
a O
common O
cause O
of O
morbidity O
and O
mortality O
in O
elderly O
patients O
, O
in O
particular O
those O
with O
advanced O
Alzheimer B-Not_AE_Candidate
' I-Not_AE_Candidate
s I-Not_AE_Candidate
dementia I-Not_AE_Candidate
. O

LATUDA O
and O
other O
antipsychotic O
drugs O
should O
be O
used O
cautiously O
in O
patients O
at O
risk O
for O
aspiration B-Not_AE_Candidate
pneumonia I-Not_AE_Candidate
. O

5.16 O
Neurological B-OSE_Labeled_AE
Adverse I-OSE_Labeled_AE
Reactions I-OSE_Labeled_AE
in O
Patients O
with O
Parkinson O
's O
Disease O
or O
Dementia O
with O
Lewy O
Bodies O
Patients O
with O
Parkinson B-Not_AE_Candidate
' I-Not_AE_Candidate
s I-Not_AE_Candidate
Disease I-Not_AE_Candidate
or O
Dementia B-Not_AE_Candidate
with I-Not_AE_Candidate
Lewy I-Not_AE_Candidate
Bodies I-Not_AE_Candidate
are O
reported O
to O
have O
an O
increased O
sensitivity O
to O
antipsychotic O
medication O
. O

Manifestations O
of O
this O
increased O
sensitivity O
include O
confusion B-OSE_Labeled_AE
, O
obtundation B-OSE_Labeled_AE
, O
postural B-OSE_Labeled_AE
instability I-OSE_Labeled_AE
with O
frequent B-NonOSE_AE
falls I-NonOSE_AE
, O
extrapyramidal B-OSE_Labeled_AE
symptoms I-OSE_Labeled_AE
, O
and O
clinical O
features O
consistent O
with O
the O
neuroleptic B-OSE_Labeled_AE
malignant I-OSE_Labeled_AE
syndrome I-OSE_Labeled_AE
. O

